Efficacy News and Research

RSS

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

13 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

AvidBiotics granted U.S. and European patents concerning its DGR technology platform

AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.

13 Nov 2009

Third-quarter 2009 results announced by Neurologix

Neurologix, Inc., a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today its financial results for the third quarter and nine months ended September 30, 2009.

12 Nov 2009

Artificially increasing selenium status above the level required is unwarranted, study calls for further research

A new study from the University of Warwick has discovered taking too much of the essential mineral selenium in your diet can increase your cholesterol by almost 10%.

12 Nov 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.

12 Nov 2009

Detailed review findings of EMPOWER study to evaluate the Maestro System released

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced preliminary findings from its ongoing detailed review of its EMPOWER™ study, a randomized, double-blind, controlled pivotal study designed to evaluate the safety and efficacy of the Maestro® System in the treatment of obesity.

12 Nov 2009

MAP Pharmaceuticals to sell up to $60 million of its registered common stock to Azimuth Opportunity

MAP Pharmaceuticals, Inc. today announced that it has secured a committed equity financing facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity Ltd. MAP Pharmaceuticals is not obligated to utilize any of the $60 million facility, which has a term of 24 months.

12 Nov 2009

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today that a review of the Company's lead compound, XMT-1001, will appear in the November 12, 2009 special issue of Advanced Drug Delivery Reviews on Polymer Therapeutics: Clinical Applications and Challenges for Development.

12 Nov 2009

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Keryx Biopharmaceuticals, Inc. today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

12 Nov 2009

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

An important, ground-breaking initiative is unfolding in the global critical care community in response to the H1N1 pandemic.

12 Nov 2009

Transplantation of hESC-derived OPCs spare spinal cord tissue in the cervical lesion site: Study

Geron Corporation today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when transplanted into a rodent model of cervical spinal cord injury, reduced tissue damage within the lesion and improved recovery of locomotor function.

12 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

Severe weakness of the quadriceps is a defining feature of several neuromuscular disorders. Researchers at Nationwide Children's Hospital have shown that a gene delivery strategy that produces follistatin - a naturally occurring protein that inhibits myostatin, a growth factor expressed specifically in skeletal muscle - directly to the quadriceps of non-human primates results in long-term gene expression with muscle enhancing effects, including larger muscles with greater strength.

12 Nov 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009.

11 Nov 2009

Osteotech highlights Magnifuse bone grafting products at NASS Annual Meeting

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. To date MagniFuse has been used in 40 spinal surgeries in the United States

11 Nov 2009

TSO3 reports third quarter 2009 financial results

TSO3 Inc. ("TSO3") posted revenues of $126,162 on the sales of consumables and service for the third quarter ended September 30, 2009. There were no new shipments of sterilizers in third quarter.

11 Nov 2009

FDA accepts Sol-Gel’s Investigational New Drug Application for DER45-EV Gel

Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.

11 Nov 2009

Engineers develop technology to ensure "right first time" drug crystal formation in existing chemical reactors

Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation.

11 Nov 2009

Efficacy News and Research

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

AvidBiotics granted U.S. and European patents concerning its DGR technology platform

Third-quarter 2009 results announced by Neurologix

Artificially increasing selenium status above the level required is unwarranted, study calls for further research

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Detailed review findings of EMPOWER study to evaluate the Maestro System released

MAP Pharmaceuticals to sell up to $60 million of its registered common stock to Azimuth Opportunity

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

Transplantation of hESC-derived OPCs spare spinal cord tissue in the cervical lesion site: Study

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

Positive results from Puricore's Vashe Wound Therapy efficacy trial

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Osteotech highlights Magnifuse bone grafting products at NASS Annual Meeting

TSO3 reports third quarter 2009 financial results

FDA accepts Sol-Gel’s Investigational New Drug Application for DER45-EV Gel

Engineers develop technology to ensure "right first time" drug crystal formation in existing chemical reactors

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News